University of Toronto School of Medicine, Ontario, Canada
Dr. Igor Stagljar is a Professor in the Departments of Biochemistry and Molecular Genetics at the Donnelly Centre, University of Toronto, Canada. Prof. Stagljar started his academic career at the University of Zurich, Switzerland, and received his Ph.D. from ETH Zurich under Professors Charles Weissmann and Markus Aebi. He trained at the University of Zurich, Switzerland and the University of Washington in Seattle, USA.
As one of the world leaders in proteomics/chemical genomics, the Stagljar lab developed groundbreaking technologies, including Membrane Yeast Two-Hybrid (MYTH), Mammalian Membrane Two-Hybrid (MaMTH) and Split-Intein Mediated Protein Ligation (SIMPL). These innovations revolutionized membrane proteomic research. His lab's recent adaptations, MaMTH-DS for drug screening and SIMPL technology for protein-protein interaction targets, show potential for advancing therapeutic development.
Throughout his career, Prof. Stagljar has been an innovator and disruptor, reflected in over 140 research papers, 8 patents, and recognition as one of the top inventors in Canada. His lab's work spans proteomics, chemical biology, membrane transport and cancer signaling, contributing seminal papers to leading scientific journals.
Focus area:
chemical genomics, high-throughput screens, AI-assisted drug discovery, small GTPases, receptor tyrosine kinases, membrane transport, ABC transporters
Disclosure information not submitted.
Tuesday, February 6, 2024
10:00 AM – 10:30 AM EST